Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Ruxolitinib in Metastatic Triple-Negative Breast Carcinoma: NCT06008275 Clinical Landscape Report 2026
16 October 2026
NCT06008275 clinical landscape for Metastatic Triple-Negative Breast Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development…
9 min read
Pembrolizumab in Residual Neoplasm: NCT06005818 Clinical Landscape Report 2026
16 October 2026
NCT06005818 clinical landscape for Residual Neoplasm: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Zanubrutinib in Diffuse Large B-Cell Lymphoma: NCT06005870 Clinical Landscape Report 2026
16 October 2026
NCT06005870 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Temozolomide in Glioblastoma Multiforme: NCT06012695 Clinical Landscape Report 2026
16 October 2026
NCT06012695 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CD70 CAR-T cells(Chongqing Precision Biotech) in Ovarian Cancer: NCT06010875 Clinical Landscape Report 2026
16 October 2026
NCT06010875 clinical landscape for Ovarian Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
MBRC-101 in Pancreatic adenocarcinoma: NCT06014658 Clinical Landscape Report 2026
16 October 2026
NCT06014658 clinical landscape for Pancreatic adenocarcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fludarabine Phosphate in High grade B-cell lymphoma: NCT06014073 Clinical Landscape Report 2026
16 October 2026
NCT06014073 clinical landscape for High grade B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cyclosporine in Acute Myeloid Leukemia: NCT06013423 Clinical Landscape Report 2026
16 October 2026
NCT06013423 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Anlotinib Dihydrochloride in Breast Cancer: NCT06015126 Clinical Landscape Report 2026
16 October 2026
NCT06015126 clinical landscape for Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
QH104 in Glioblastoma Multiforme: NCT06018363 Clinical Landscape Report 2026
16 October 2026
NCT06018363 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Lenalidomide in High grade B-cell lymphoma: NCT06015880 Clinical Landscape Report 2026
16 October 2026
NCT06015880 clinical landscape for High grade B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cemiplimab-RWLC in Uveal Melanoma: NCT06022029 Clinical Landscape Report 2026
16 October 2026
NCT06022029 clinical landscape for Uveal Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.